Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radiprodil - GRIN Therapeutics

Drug Profile

Radiprodil - GRIN Therapeutics

Latest Information Update: 03 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GRIN Therapeutics
  • Class Antiepileptic drugs; Behavioural disorder therapies; Non-opioid analgesics; Small molecules
  • Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Behavioural disorders; Seizures

Most Recent Events

  • 30 Apr 2024 GRIN Therapeutics plans a phase Ib/IIa trial for Seizures and Behavioral Symptoms (In children, In adolescents, In infants, Treatment-resistant) in Australia, Belgium, Canada, Italy, Poland, Spain, United Kingdom (PO) (NCT06392009)
  • 28 Nov 2022 Phase-I clinical trials in Behavioural disorders (In infants, In children) in Spain, Germany (PO) (EudraCT2022-000317-14)
  • 28 Nov 2022 Phase-I clinical trials in Seizures (In children, In infants) in Germany, Spain (PO) (EudraCT2022-000317-14)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top